NCT06352242Recruiting
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
La Trogocytose Est-elle un Marqueur prédictif de la réponse Aux Cellules CAR-T Dans Les Lymphomes Diffus à Grandes Cellules B ?
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment. To date, there is no predictive test for therapeutic response after injection of CAR-T cells. Recent studies have shown that the level of trogocytosis by immune cells correlates with the persistence of tumor cells in patients with hematological malignancies. Our main objective is to identify a phenotypic "signature" of trogocytosis predictive of therapeutic response 6 months after injection of CAR-T cells for DLBCL.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 85 (estimated)
- First submitted
- 26 Mar 2024
- Start date
- May 2024
- Primary completion date
- Feb 2027
- Lead sponsor
- University Hospital, Montpellier
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT06352242
What you commit to
- Study type: Interventional
- Planned participants: 85
- From May 2024 to the primary completion date, Feb 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who do not meet all the inclusion criteria,
- Pregnant or breast-feeding patient,
- Patient unable to follow the procedures and/or frequency of visits planned in the trial, for psychological, family, social or geographical reasons,
- Patient unable to consent freely to inclusion, under guardianship, curatorship or safeguard of justice.
Who the study is looking for
- For patients
- Patient who has given free and informed consent in writing for inclusion in the non-interventional CART-BANK protocol, and orally for the CARTROG protocol,
- Patients over 18 years of age at the time of inclusion,
- Diagnosis of LDGCB,
- Decision to treat with anti-CD19 CAR-T cells,
- Patient affiliated to or benefiting from a social security scheme.
- For healthy volunteers:
- Given free and informed oral consent for inclusion in the CARTROG protocol,
- Donor between 18 and 70 years of age at the time of inclusion,
- No history of solid cancer or hematological malignancy,
- No known chronic pathology (e.g. hypertension, diabetes, etc.) and no daily treatment,
- No surgical treatment within the last 6 months.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical hematology department, University Hospital Coordinator of this site? Confirm its status | Montpellier | France | Recruiting |
| Clinical Investigation Center, University Hospital Coordinator of this site? Confirm its status | Montpellier | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.